Vaccine effectiveness in Michigan: how well flu, COVID-19 and other respiratory vaccines work
Official title: RFA-IP-22-004:Michigan-Ford Initiative to Measure Vaccine Effectiveness (MFIVE): Seasonal Influenza, COVID-19 and Respiratory Virus Vaccines
Funded at University of Michigan at Ann Arbor · NIH-11379696 · Data updated 2026-11-12
This project tests how well vaccines against flu, COVID-19, and other respiratory viruses prevent medically attended illness in people visiting outpatient clinics in Southeastern Michigan.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | September 30, 2022 |
| Project end | September 29, 2027 |
| Funding year | 2026 |
| Award (this year) | $1,316,666 |
| NIH project number | 5U01IP001193-05 |
| Project ID | NIH-11379696 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults or children visiting ambulatory clinics in Southeastern Michigan for acute respiratory illness and who have known vaccination status.
✕Less likely to help
People not seeking care for respiratory illness or those outside the study region may not directly benefit.
What this research studies
If you live in Southeastern Michigan and visit outpatient clinics or testing centers for respiratory symptoms, this project will collect and test samples to see how well current vaccines protect you from illness. Researchers will combine blood antibody data, virus sequencing, and testing for other respiratory viruses to refine measures of vaccine effectiveness in real time. The study builds on a decade of surveillance and uses a test-negative approach to compare vaccinated and unvaccinated patients who test positive or negative for SARS-CoV-2 and influenza. Enrollment will occur across multiple clinics serving diverse communities to ensure findings reflect the region.
Why it matters
Potential benefit: If successful, this work could provide timely information on how well vaccines protect people in real-world settings and guide future vaccination strategies.
How similar studies have gone: Previous test-negative VE studies have informed vaccination policy and this approach is well-established in the field.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Martin, Emily Toth — University of Michigan at Ann Arbor
- Study coordinator: Martin, Emily Toth
Related research
Other NIH-funded projects on the same topics.
-
Motivational interviewing to increase COVID-19 and flu vaccination
This project teaches primary care providers conversational skills to help more adults, especially those in vulnerable communities, feel comfortable getting COVID-19 and flu shots.
-
Platform to Measure How Well Flu and COVID-19 Vaccines Work in Underserved Arizona Communities
A research effort in Arizona will track how well flu and COVID-19 vaccines protect people in underserved communities, including diverse adults and immunocompromised individuals.
-
Credible vaccine protection measures for Flu, COVID-19, and other respiratory viruses in Texas ambulatory care
This project looks at how well flu and COVID-19 vaccines protect people from visiting clinics for acute respiratory illnesses in Central Texas.
-
Platform to Measure How Well Seasonal Flu, COVID-19, and Other Respiratory Vaccines Prevent Illness in Real-Life Settings
This grant supports a national effort to track how well respiratory vaccines work in everyday clinics and homes.
-
How well flu, COVID-19, and other respiratory vaccines protect people in southeastern Michigan
This project checks how well seasonal flu, COVID-19, and other respiratory vaccines protect people who visit clinics for coughs, colds, or breathing problems in southeastern Michigan.
-
How flu, COVID-19, and other respiratory virus vaccines protect against outpatient respiratory illness in Central Texas
This project measures how well flu, COVID-19, and other respiratory virus vaccines prevent people in Central Texas from getting sick enough to seek outpatient medical care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.